CATEGORY: BRAIN & MENTAL HEALTH
Adults with migraine who took the drug ubrogepant during the warning phase—the hours of fatigue, neck pain or light sensitivity many people feel before the pain arrives—escaped moderate or severe headache over the next 24 hours after 46% of treated warning episodes, versus 29% when they had unknowingly taken a placebo, in a randomized US trial.1
The Hours Before the Pain
A migraine attack often announces itself. This opening act, called the prodrome, is a stretch of warning symptoms—tiredness, neck stiffness, trouble concentrating, sensitivity to light or sound, yawning, food cravings—that in many people reliably ends in head pain within a few hours. Ubrogepant is a tablet already used to treat attacks once the pain has started. It works by blocking CGRP, a chemical messenger that nerve cells release during a migraine to dial pain signaling up—think of intercepting the messenger on the way to the alarm rather than waiting for the alarm to sound. The trial asked whether taking that blocker during the warning hours could keep the headache from arriving at all.1
Each Person Answered the Question Twice
Researchers enrolled 518 adults, aged 18 to 75, who had lived with migraine for at least a year and could reliably tell when an attack was coming. Each participant treated two separate warning episodes: for one they took a single 100-milligram ubrogepant tablet, for the other an identical-looking placebo, in an order assigned by chance, with neither participants nor researchers knowing which was which. Because every person served as their own comparison—same brain, same disease, two differently treated warnings—the design filters out much of the person-to-person variation that muddies migraine research. In all, 477 people who treated qualifying episodes were included in the analysis, and each episode was tracked for 48 hours.1
Escaping the Bad Headache, One Warning in Two
When the warning phase was treated with ubrogepant, no moderate or severe headache developed within 24 hours in 46% of episodes—190 of 418—compared with 29% of placebo-treated episodes, or 121 of 423. The gap held over the full two days: 41% versus 25% of episodes stayed free of moderate or severe headache through 48 hours. The honest flip side is that a majority of treated warnings still ended in a bad headache; the tablet raised the odds of escaping one from roughly one in three to nearly one in two, rather than switching attacks off entirely. Side effects within 48 hours were modestly more common with the drug—17% of episodes versus 12%—and mostly amounted to nausea, fatigue or dizziness.1
The Warning Symptoms Themselves Eased
A later analysis of the same trial looked at what happened to the prodrome symptoms before any headache came. Treated episodes were more often free of neck pain three hours after the dose (28.9% versus 15.9%), free of sound sensitivity at four hours (50.7% versus 35.8%), and free of light sensitivity at two hours (19.5% versus 12.5%).2 Those results are exploratory rather than definitive, but they point the same way as the main finding. One boundary is worth stating plainly: the trial enrolled only people who could recognize their own warning signs dependably, so the result speaks to that group—not to everyone with migraine, since some attacks arrive with no usable warning at all.1
Key Takeaways
- In a randomized crossover trial of 477 US adults with migraine, taking ubrogepant during the warning phase left 46% of episodes free of moderate or severe headache over 24 hours, versus 29% with placebo—and 41% versus 25% over 48 hours.
- The drug did not abolish attacks: most treated warning episodes still ended in a bad headache, but the chance of escaping one rose from about one in three to nearly one in two.
- The finding applies to people who can reliably recognize their own warning symptoms; participants had to demonstrate that before enrolling.
- Side effects were modestly more common with the drug (17% versus 12% of episodes) and were mostly mild—nausea, fatigue or dizziness—while a follow-up analysis found the warning symptoms themselves eased more often after the tablet.
References
- Dodick DW, Goadsby PJ, Schwedt TJ, et al. Ubrogepant for the treatment of migraine attacks during the prodrome: a phase 3, multicentre, randomised, double-blind, placebo-controlled, crossover trial in the USA. The Lancet. 2023;402(10419):2307–2316. link
- Goadsby PJ, Ailani J, Dodick DW, et al. Ubrogepant for the treatment of migraine prodromal symptoms: an exploratory analysis from the randomized phase 3 PRODROME trial. Nature Medicine. 2025;31(7):2179–2185. link